Even though the primary studies reported the manageable safety profile of tofacitinib over the treatment periods[10,16,18,19], this meta-analysis has established the significant association of tofacitinib with infections, decreased level of neutrophil and increased levels of hemoglobin, creatinine and liver enzymes (ALT and AST). The gene discussed is GPT; the disease is infection.